EUCTR2019-002319-25-IT进行中（未招募）1 期
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged DuringTransfection (RET) Activation (LIBRETTO-201) - LIBRETTO-201
OXO ONCOLOGY INCORPORATED0 个研究点目标入组 450 人开始时间: 2021年9月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Major Inclusion Criteria:
- •1. Patients with a locally advanced or metastatic solid tumor with RET activation who:
- •Are not eligible for an ongoing selpercatinib clinical trial (e.g., for clinical, geographic or financial reasons or due to cohort closure), but are deemed appropriate candidates to receive selpercatinib treatment by the Investigator and the Sponsor, and
- •Have progressed on or are intolerant to standard therapy, or
- •No standard therapy exists, or
- •In the opinion of the Investigator, are not candidates for or who would be unlikely to derive significant clinical benefit from standard therapy
- •Patients eligible for LIBRETTO-001 and/ or Phase 3 trials who are being considered for the EAP must be discussed with the Medical Monitor prior to screening.
- •2. Evidence of an activating RET gene alteration from a laboratory with Clinical Laboratory Improvement Act (CLIA), International Organization for Standardization (ISO)/independent ethics committee (IEC), College of American Pathologists (CAP), or other similar certification.
- •3. Eighteen years of age or older at the time of consent.
- •4. Adequate hematologic, renal and hepatic function as defined in Section 6.1.
- •5. Ability to provide consent.
- •6. Provision of a signed informed consent prior to any protocol specific procedures. Patients already receiving selpercatinib who enroll in this protocol must be reconsented and sign the consent form for this expanded access protocol.
- •7. Patients who are deemed eligible by the Sponsor’s medical monitor.
- •8. Willingness of men and women of reproductive potential to observe double effective birth control methods, defined as one used by the patient and another by his/her partner, for the duration of treatment and for 3 months following the last dose of study treatment (refer to Section 1.6.3).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 350
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Major Exclusion Criteria:
- •1. Investigational agent (via clinical trial) or anticancer therapy within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of selpercatinib unless considered by the Investigator to be safe, within the best interest of the patient and with prior Sponsor approval.
- •2. Clinically significant active cardiovascular disease (including NYHA class III/IV heart failure, stroke, severe valvular disease or uncontrolled hypertension defined as = 140/80 sustained over multiple readings) or history of myocardial infarction within 6 months prior to Cycle 1, Day 1 (C1D1); ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia’s formula (QTcF) interval > 470 msec. Patients who meet this criteria may be enrolled (with a modified dosing strategy) if a clinical rationale exists which is reviewed and agreed upon by the Sponsor.
- •3. Current treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (refer to Section 1.6.3).
- •4. Current treatment with proton-pump inhibitors (PPIs). Note: Treatment with PPIs must be stopped 1 or more weeks prior to the first dose of selpercatinib.
- •Complete EAP eligibility criteria are presented in Section 4.
研究者
相似试验
已完成
Unknown
Multi-Center Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activatioocally advanced or metastatic solid tumors with activating RET alterations (and other evidence of RET activation).JPRN-jRCT2080225226oxo Oncology, Inc.,Wholly owned subsidiary of Eli Lilly and Company / CMIC Co., Ltd.50
进行中（未招募）
不适用
An expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.EUCTR2011-002731-26-ITOVARTIS FARMA700
进行中（未招募）
1 期
Access Program for Asfotase AlfaHypophosphatasiaEUCTR2015-000809-39-FRAlexion Pharma International Sàrl100
已完成
不适用
MULTICENTER PROGRAM EXTENDED OPEN MODALITY OF ACCESS WITH ALPHA 2A (RO 25-8310) AS A MONOTERAPY AND COMBINATION THERAPY WITH RIVABIRIN (RO 20-9963) IN PATIENTS WITH CHRONIC HEPATITIS C-B171 Acute hepatitis CAcute hepatitis CB171PER-067-01PRODUCTOS ROCHE Q.F.S.A.,
Approved For Marketing
不适用
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.